Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (May 2021)
30 slides from Bio-gene Technology's investor presentation, May 2021
Slide 1: Bio-Gene Technology Limited Corporate Presentation May 2021
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED MAY 2021 Corporate Presentation PRESENTED BY Richard Jagger Chief executive Officer & Managing Director
Slide 2: Key Investment Highlights
CORPORATE PRESENTATION KEY INVESTMENT HIGHLIGHTS Proprietary insecticide Expanding efficacy, Large addressable technology toxicity and markets Naturally derived manufacturing data where insecticide chemistry, with novel mode to support international resistance is a growing of action regulatory submi
Slide 3: Addressing Significant Global Challenges
CORPORATE PRESENTATION ADDRESSING SIGNIFICANT “At present, there are more than 16,000 documented cases of insecticide resistance involving more than 600 insect and mite species GLOBAL CHALLENGES that have developed resistance to at least one insecticide. Insecticides allow control of agricultural pe
Slide 4: The Value of Insecticides
CORPORATE PRESENTATION Food Security & Public Health Growing Population Current global population is 7.7 billion, growing at 70 million p.a. It is THE VALUE OF Challenges Of anticipated that global population will reach nearly 10 billion by 20501 Climbing average temperatures and other weather event
Slide 5: Our Technology Addresses These Challenges and Targets Growing Global Markets
CORPORATE PRESENTATION OUR TECHNOLOGY ADDRESSES THESE CHALLENGES AND TARGETS GROWING GLOBAL MARKETS Bio-Gene’s insecticide platform has potential Crop Protection Food, Fibre & Grain application in large, global market segments Storage 52% estimated to represent a total addressable market Includes gr
Slide 6: Our Technology Platform
CORPORATE PRESENTATION OUR TECHNOLOGY PLATFORM We are developing two products that allow entry into five key market segments QcideTM FlavocideTM Natural Compound Nature Identical Compound Both of our products An extract of a specific cultivar of BGT has developed a proprietary have potential applica
Slide 7: Our Proprietary Chemistry Represents a Step-Change for Resistant Pest Control
CORPORATE PRESENTATION OUR PROPRIETARY CHEMISTRY REPRESENTS A STEP-CHANGE FOR RESISTANT PEST CONTROL Naturally Derived Chemistry Safe Chemistry Efficacy Novel Mode of Action QcideTM is a natural compound Excellent safety profile based on Testing to date confirms potential Operates via a novel and Fl
Slide 8: Our Strategic Objective
CORPORATE PRESENTATION OUR STRATEGIC Generate multiple revenue streams from technology licensing fees, milestone payments and royalties by OBJECTIVE Securing & owning active ingredient product registrations Working with strong commercial partners on product development; marketing and distribution De
Slide 9: Creating Multiple Product Development Opportunities
CORPORATE PRESENTATION CREATING MULTIPLE Bio-Gene can generate income and Multiple Material Transfer Agreements PRODUCT DEVELOPMENT incremental company value as provide the opportunity for agreements to agreements are signed with commercial be developed across various market partners segments with n
Slide 10: Current Developments Across Our Key Markets
CORPORATE PRESENTATION CURRENT DEVELOPMENTS ACROSS OUR KEY MARKETS CROP PROTECTION STORED GRAIN PUBLIC HEALTH CONSUMER ANIMAL HEALTH Advances in TOXICOLOGY studies towards & SAFETY registration MoA studies completed Scale up towards commercial levels MANUFACTURING Establishing efficacy and Additiona
Slide 11: Stored Grain Pest Evaluation Program
CORPORATE PRESENTATION STORED GRAIN PEST EVALUATION Stage 1 identified PROGRAM optimum product combination for control of the major pest, the Stage 2 testing AUSTRALIA Lesser grain borer demonstrated that Flavocide in combination with other products Stage 3 (field) testing has effectively controls 5
Slide 12: Mosquito Evaluation Program
CORPORATE PRESENTATION MOSQUITO EVALUATION Agreement entered into in April 2020, evaluating Flavocide and Qcide for PROGRAM use in public health mosquito control in Testing commenced in September 2020 to assess North, South and Central various solvents as base THE AMERICAS America carriers (results
Slide 13: Multi Faceted Approach to Create Barriers to Entry
CORPORATE PRESENTATION BIO-GENE USES A MULTI FACETED APPROACH TO Bio-Gene uses a platform New patent applications will CREATE BARRIERS TO ENTRY of intellectual property to add value to our succeed existing patents approaching expiry AROUND OUR PROPRIETARY technology and future customers TECHNOLOGY 0
Slide 14: Registration of Bio-Gene Products
CORPORATE PRESENTATION REGISTRATION OF Advanced BIO-GENE PRODUCTS Chemistry Physical/chemical properties determined; manufacture/production & Manufacture processes defined Efficacy & Safety Efficacy for specific use patterns demonstrated; product formulations developed Bio-Gene is making positive Oc
Slide 15: Manufacturing
CORPORATE PRESENTATION MANUFACTURING Qcide Flavocide Key molecule found in rare cultivar of Nature Identical molecule found in Eucalyptus sp. Australian Flora, but not in commercial - quantities Unusually high levels of key ingredient - found in oil of leaf Synthesis process developed with - assista
Slide 16: Funding Position
CORPORATE PRESENTATION FUNDING POSITION Sources of future funding: Shares on issue 153,633,357 Market capitalisation $27.7 million* Development Government Philanthropic As at December 31, 2020, and commercial grants organisations Cash on hand partnerships focused on public health solutions A$5.0 mil
Slide 17: Board Members & Management
BOARD MEMBERS & MANAGEMENT Robert Klupacs Richard Jagger Peter Beetham James Joughin Interim Chairman CEO & Managing Director Non-Executive Director Non-Executive Director • 30+ years corporate experience in • 25+ years working in agriculture globally • 30+ years experience in bio-agriculture • High
Slide 18: A Clear Road Map for Adding Value: Short Term
CORPORATE PRESENTATION A CLEAR ROAD MAP CY21 Q4 FOR ADDING VALUE CY21 Q3 SHORT TERM ▪ Confirmation of yield improvements CY21 Q2 via extraction process at Qcide ▪ Flavocide 5-batch harvest manufacturing ▪ BASF / GRDC stage CY21 Q1 analysis (for 3 results registration) ▪ Flavocide ▪ Qcide Tree planti
Slide 19: A Clear Road Map for Generating Value 2024-2026
CORPORATE PRESENTATION A CLEAR ROAD MAP FOR GENERATING VALUE 2024-2026 CRITICAL VALUE ADDING & DE-RISKING STEPS 2022-2024 2021-2022 • First regulatory approval and 2020-2021 • Additional commercial sales application testing - • Additional 2018-2020 • Manufacturing scale- internal and with registrati
Slide 20: Summary
CORPORATE PRESENTATION SUMMARY Bio-Gene is successfully advancing a Bio-Gene’s technology addresses The global market for insecticides is naturally derived, novel and significant environmental, food ~ US$31 billion and growing proprietary class of insecticide safety and public health challenges chem
Slide 21: Bio-Gene Technology Limited Contact
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED CONTACT RICHARD JAGGER CHIEF EXECUTIVE OFFICER richardj@bio-gene.com.au
Slide 22: Appendix
CORPORATE PRESENTATION APPENDIX 22
Slide 23: About Bio-Gene
APP CORPORATE PRESENTATION ABOUT BIO-GENE… Our novel platform technology We are progressing towards Bio-Gene is developing has a unique mode of action and product registrations and, in the next generation of is based on naturally occurring parallel, identifying commercial beta-triketones, a type of
Slide 24: Establishing a Novel Mode of Action Is a Major Milestone
APP CORPORATE PRESENTATION ESTABLISHING A NOVEL MODE OF ACTION IS A MAJOR MILESTONE The confirmation of a definitive new MoA represents a key milestone in the value proposition for potential commercial partners who have a need for new MoA to The Mode of Action (MoA) defines the process of how an com
Slide 25: Capitalising on Platform Technology
APP CORPORATE PRESENTATION CAPITALISING ON PLATFORM TECHNOLOGY Bio-Gene has the potential to replicate the success of Nihon’s platform technology developed for the Diamide insecticide class (last significant new Mode of Action) Nihon Nohyaku development program First products were developed with com
Slide 26: Significance of Pests in Stored Grain
APP CORPORATE PRESENTATION SIGNIFICANCE OF PESTS IN STORED GRAIN PRODUCER Highly Resistant Grain Lesser Grain Borer Borer Populations FIELD LOSSES Pest & diseases 20-40% in Potential Crop Yield PRE-PROCESSING Broken grans & excessive dehulling A beetle which destroys stored grain and cereal products
Slide 27: Additional Interest in Our Technology
APP CORPORATE PRESENTATION ADDITIONAL INTEREST IN OUR TECHNOLOGY Multiple Material Transfer Agreements (MTAs) in place with companies that cover a range of Public Consumer Animal geographic markets and span our Health Products Health five key end-use markets Crop Grain Protection Storage These agree
Slide 28: Registration of Bio-Gene Products
CORPORATE PRESENTATION APP REGISTRATION OF BIO-GENE PRODUCTS In Australia, Bio-Gene must satisfy the Australian Preliminary results can be used to confirm likely future data Pesticides & Veterinary Medicines Authority (APVMA) requirements with the APVMA, with the aim to streamline process for Ag-Che
Slide 29: Key Priorities for the Current 12 Months
APP or out CORPORATE PRESENTATION KEY PRIORITIES FOR THE CURRENT 12 MONTHS Generate additional Undertake 5-batch analysis testing Successfully complete stage 3 trial Clarification of the data package toxicology data – supports on scaled up manufacturing process work as part of Australian stored requ
Slide 30: Disclaimer
CORPORATE PRESENTATION DISCLAIMER The information contained in this document (“Document”) has been prepared by Bio-Gene Technologies Limited (referred to as “Bio-Gene”, “BGT” or the “Company”). The Company has authorised the distribution of this document to the recipients (“Recipients”) determined b
Bio-Gene Technology — Investor Presentation (May 2021) on 6ix